Neural stem/progenitor cells (NS/PCs) derived from human induced pluripotent stem cells (hiPSCs) are expected to be a valuable cell source for cell therapies that target central nervous system disorders. For clinical applications, NS/PCs should be induced and maintained under clinical grade conditions, which are challenging to achieve. In the present study, we established a procedure to obtain xeno-free long-term self-renewing neuroepithelial-like stem cells (xf-lt-NES cells) from feeder-free hiPSCs using a newly developed xeno-free medium, StemFit ® AS200. xf-lt-NES cells were cultured for long periods in StemFit ® AS200 while retaining normal karyotypes, NS/PC marker expression and differentiation capacity for neuronal and glial differentiation in vitro and in vivo. Furthermore, the cells were cryopreserved using a defined serum-free freezing reagent, which demonstrated the feasibility of this xeno-free culture system for large-scale lt-NES cell production and cell banking. Taken together, our system represents a promising approach for the manufacture of clinically relevant products for cell therapy using NS/PCs.
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Introduction
A number of studies have shown that the transplantation of neural stem/progenitor cells (NS/PCs) into damaged neural tissues promotes functional recovery in animal models via several mechanisms, including cell replacement and trophic support (reviewed in Lindvall and Kokaia, 2006; Nakamura and Okano, 2013) . Therefore, regenerative medicine using NS/PCs is expected to represent a novel treatment approach for central nervous system (CNS) diseases and injuries. Although human NS/PCs may be derived from fetal neural tissues and human embryonic stem cells (hESCs), there has been a potential concern regarding the clinical application of these cells because of issues related to ethical problems and/or immune compatibility (Okano et al., 2013; Okita et al., 2011; Turner et al., 2013) . Therefore, the establishment of procedures to generate humaninduced pluripotent stem cells (hiPSCs) from somatic tissues has created a new avenue for regenerative medicine for various types of disorders (Takahashi et al., 2007) . hiPSCs were initially developed by retrovirally delivered reprogramming transcription factors and harbored a potential risk of tumorigenicity as a result of random insertional mutations by genomic integration of retrovirus (Nori et al., 2015; Okano et al., 2013) . Recently, there has been substantial progress related to the procedures used to generate iPSCs, which would overcome the potential adverse effects of random integration of retrovirus during the iPSC generation process. For example, successful reprogramming of somatic cells using non-integrating episomal vectors (Okita et al., 2011 (Okita et al., , 2013 and Sendai virus (Fusaki et al., 2009; Seki et al., 2010) has enabled the generation of safer transgene-free or integration-free hiPSCs.
